5 Results for "

pacritinib

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "pacritinib" in MCE Product Catalog:

19
19 Publications Verification
Cat. No.: HY-16379
CAS No.: 937272-79-2
Synonyms: SB1518
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM).
19
19 Publications Verification
Cat. No.: HY-16379B
CAS No.: 1228923-42-9
Synonyms: SB1518 citrate
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib citrate also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .
Cat. No.: HY-16379S
Synonyms: SB1518-d4
Pacritinib-d8 (SB1518-d8) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM).
Cat. No.: HY-16379R
CAS No.: 937272-79-2
Synonyms: SB1518 (Standard)
Research Areas:  

Cancer

Pacritinib (Standard) is the analytical standard of Pacritinib. This product is intended for research and analytical applications. Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).
Cat. No.: HY-16379A
CAS No.: 1228923-43-0
Synonyms: SB1518 hydrochloride
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .